UCLB announces winners of the UCL Enterprise Awards for Enterprise
Professor Nathwani has been awarded the 2014 UCL Business Award for his work on Factor VIII gene therapy program for haemophilia A which has been licenced to BioMarin Pharmaceuticals Inc.
Upon accepting the award for Professor Nathwani, Professor Edward Tuddenham said, “UCLB have wide experience in taking the academic research of UCL partners through to translation in various fields of biomedicine and they were able to support us in the way we took forward the negotiations. This was very beneficial in the fact that we fairly rapidly came through to an agreed basis of continued collaboration.”
The UCLB One to Watch award was presented to Professor David Patterson and Dr Mark Leaning for their work on Helicon Health.
Helicon Health has developed unique systems and tools that enable better quality shared care closer to home for patients with long-term cardiovascular conditions. The company’s proven integrated approach, focused initially on stroke prevention, combines patient management tools and advisory systems with accredited learning and clinical governance. It is being welcomed by a growing number of Clinical Commissioning Groups (CCGs).
Accepting the award, Dr Patterson said, “UCLB have been involved from a very early stage, we value their partnership hugely, they have offered us expertise that we would not have easily obtained elsewhere. To be associated with UCLB is a huge benefit to us as a company. This award is amazing at an early stage of the development of our company; this means a tremendous amount to all of us.”
About UCL Business PLC
UCL Business PLC (UCLB) is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK’s top research-led universities. UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. UCLB has a strong track record in commercialising medical technologies and provides technology transfer services to UCL’s associated hospitals; University College London Hospitals, Moorfields Eye Hospital, Great Ormond Street Hospital for Children and the Royal Free London Hospital. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from laboratory to market.
For further information, please visit: www.uclb.com